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Abstract
Abatacept (CTLA4–Ig) is a novel fusion protein designed to
modulate the T cell co-stimulatory signal mediated through the
CD28–CD80/86 pathway. Clinical trials have provided preliminary
evidence of the efficacy of this compound in the treatment of
rheumatoid arthritis. This review describes the molecular and
biologic bases for the use of abatacept in rheumatoid arthritis and
summarizes the current clinical data on its safety and effectiveness
in this disease.
Introduction
Recent clinical research in rheumatoid arthritis (RA) has led
to significant advances in care using inhibitors of the
circulating proinflammatory cytokines tumor necrosis factor
(TNF)-α and interleukin-1. However, the failure of such agents
to control disease in all patients has fostered a search for
other approaches to ameliorate disease activity. Although
T cells are the most abundant inflammatory cells in the RA
joint and exhibit phenotypic markers of activation, there is
little or no evidence of efficacy of anti-CD4+ T lymphocyte
strategies, even though they have resulted in prolonged
depletion of peripheral CD4+ T cells [1]. In contrast to
depletion, it is possible that modulation of T cell function,
possibly by altering the stimulatory pathway or the Th1:Th2
ratio, may be therapeutically beneficial. An alternate approach,
in which the activity of antigen-specific T cells is controlled by
targeting co-stimulatory molecules, has now been developed,
and preliminary studies have shown it to be effective at
controlling the clinical signs and symptoms of RA [2,3].
Molecular background
Activation of T cells requires two distinct signals. The first is
an antigen-specific interaction between the T cell receptor
and nominal antigen presented in the context of the MHC on
the surface of an antigen-presenting cell. The second signal
may be provided through a number of potential co-stimulatory
molecules, of which CD28 may be the most important. Co-
stimulation is especially important for the initial T cell
response, and its effects are mediated by promoting
proliferation and survival. Thus, therapies targeting co-
stimulatory signals have the potential to target specific T cell
responses, even when the actual nature of the antigen
involved is unknown. Such an approach would be potentially
useful in RA, in which the initial trigger for the autoimmune
response remains unclear.
One of the most prominent T cell co-stimulatory signals is
mediated through the CD28–CD80/86 pathway, which
regulates interleukin-2 production and the expression of anti-
apoptotic molecules, such as Bcl-xL [4,5]. CD28 is present
on most T cells and it binds to both CD80 (B7-1) and CD86
(B7-2), which are present on antigen-presenting cells,
including dendritic cells, B cells, and macrophages. These
ligands are also expressed on activated T cells and are
present on T cells obtained from RA joint, suggesting a self-
sustaining mechanism for T cell activation [6]. Engagement
with these ligands provides the second signal required for
maximal T cell activation, and the absence of a co-stimulatory
signal may result in anergy and apoptotic cell death.
Cytotoxic T lymphocyte-associated antigen (CTLA)4 (CD152),
which is upregulated on T cells following their activation, also
interacts with CD80 and CD86, providing an important
mechanism for regulating T cell function [7,8]. Not only does
CTLA4 permit interruption of the activating CD28 pathway
but it may also provide important negative signals that permit
long-term tolerance. CD28/B7 interactions are critical for the
generation of CD4+, CD25+, CTLA4+ T regulatory cells, and
signaling through CTLA4 may promote the release of
immunoregulatory cytokines such as TGFβ [5,9]. Of interest,
CTLA4 is expressed on T cells in the RA joint [6], supporting
the potential importance of this pathway in regulating T cell
activation in RA.
The regulatory effects of interrupting CD28 interactions with
CD80/86 have been harnessed in recombinant molecules
(CTLA4–immunoglobulin [Ig]) that combine the extracellular
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domain of human CTLA4 with a portion of the Fc domain of
IgG1 [10]. One of these fusion proteins, abatacept, binds
CD80 more avidly than CD86. A second-generation version
of this molecule (LEA29Y), with two amino acid mutations,
has been developed to have increased binding avidity for
CD86 [2]. This change may be important because CD86
appears to be the dominant co-stimulatory ligand in a number
of experimental models, and, in treating mouse models of
autoimmune disease, inhibition of CD86 was more effective
than inhibition of CD80 [5]. CTLA4–Ig also interrupts
signaling through cell surface CTLA4, which theoretically
could affect the development of T regulatory cells and antigen
specific tolerance. However, inhibition of signaling through
CTLA4 has also been shown to promote Th2 development,
which may be beneficial in RA [11].
Preclinical studies
CTLA4 shares significant sequence homology between the
human and murine versions of the molecule, so that fusion
compounds containing this ligand can be effectively studied
in murine models of a variety of human diseases. CTLA4–Ig
has been studied in preclinical transplant models as well as in
models of systemic lupus erythematosus, experimental
allergic encephalitis (a murine model of multiple sclerosis),
and collagen induced arthritis [12–16]. In the B/W murine
model of lupus, treatment with CTLA4–Ig delayed the onset
of renal disease and prolonged survival when treatment was
given before the development of nephritis [12]. Combination
therapy with CTLA4–Ig and cyclophosphamide improved
proteinuria and prolonged survival when it was given to mice
that already had advanced renal disease [17]. In that
experiment, the combination of CTLA4–Ig and cyclophospha-
mide was shown to be more effective than either therapy
given alone.
In the collagen induced arthritis model, infusion of a human
CTLA4–murine IgG2a Fc was shown to limit both clinical and
histopathologic manifestations of joint disease when it was
given before the animals were immunized with collagen [16].
In these experiments, rats were immunized with a single
intradermal injection of bovine type II collagen. Clinical
evidence of hindpaw disease first appears in these rats at
day 10 after immunization, with complete ankylosis of the
hindpaws by days 16–18 in 100% of animals. Intraperitoneal
injections of 1 mg/kg of the CTLA4–Ig fusion protein, begun
1 day before collagen immunization and continued every
other day through to day 10, completely abrogated clinical
and histological signs of arthritis. These observations
suggest that CD28–CD80/86 interactions are important in
the initiation of the arthritis. Supporting these observations,
CD28 deficient mice were resistant to the induction of
collagen induced arthritis [18]. Interestingly, up to 20% of T
cells in the RA joint may be CD28 negative [6], and the
frequency of peripheral blood CD4+CD28– T cells in
patients with RA corresponds with extra-articular
manifestations [19].
Pilot studies
The CTLA4–Ig fusion protein abatacept has been specifically
studied in human RA. In a dose ranging pilot study of patients
with active RA [2], both abatacept and LEA29Y produced
dose dependent reductions in the clinical manifestations of
disease. A total of 214 patients were entered into this three
arm study. A total of 90 received abatacept at doses of
0.5 mg/kg, 2 mg/kg, and 10 mg/kg; 92 received LEA29Y at
the same doses; and 32 received placebo infusions. Infusions
were given at baseline, week 2, week 4, and week 8.
The study population in this trial was predominantly female
(75%), Caucasian (91%), and receiving corticosteroids at an
allowed dose of 10 mg/day or less (90%). Their mean
disease duration was only 3.2 years but they had very active
disease, with a mean of 30.3 tender and 21.9 swollen joints
at randomization. The mean baseline level of C-reactive
protein was 4.0 mg/dl. Most patients (79%) had been treated
with methotrexate, which was discontinued per protocol at
least 4 weeks before the first dose of study drug.
There was a dose dependent response to both compounds
in this study (Fig. 1). For abatacept, 44% of the patients in
the 2 mg/kg group and 53% in the 10 mg/kg group achieved
an American College of Rheumatology (ACR) 20 response at
12 weeks (the primary outcome of the study) as compared
with 32% in the placebo arm. Response was seen across all
of the components in the ACR core set, with the two highest
dose treatment groups for each compound exhibiting a
consistently higher percentage improvement than placebo.
The 10 mg/kg dose of abatacept was generally more
effective than 2 mg/kg.
Of the patients included in the study, 19% withdrew before
the 12 week visit. The most common reason for discontinua-
tion, worsening arthritis, led to the withdrawal of 32% of the
placebo group, 13% of the patients treated with abatacept,
and 4% of the patients treated with LEA29Y. Adverse events
were similar in the active drug and placebo groups. Peri-
infusional adverse events occurred in about 30% of those in
each of the three treatment groups. Four patients receiving
abatacept withdrew because of adverse events: two because
of worsening arthritis (one each in the 0.5 mg/kg and
2 mg/kg groups), one because of an anxiety attack, and one
(in the 0.5 mg/kg group) because of breast cancer
discovered at week 8. One patient treated with LEA29Y
withdrew because of a viral upper respiratory tract infection.
Fifteen serious adverse events occurring in 12 patients were
judged by the investigators not to be due to the study drugs,
including a septic elbow in one patient 88 days after the last
infusion of abatacept 2 mg/kg and 40 days after the joint was
injected with corticosteroids. No drug-specific antibodies
against either compound were detected.
In a second pilot study [20], 121 patients with active RA
taking etanercept 25 mg subcutaneously twice weekly wereS23
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randomly assigned to receive either monthly infusions of
abatacept 2 mg/kg or placebo. The lower dose was chosen
because of safety concerns regarding co-administration of
the two biologic response modifiers. The patients included in
this trial had longstanding disease (mean 13 years) and
active synovitis despite etanercept (mean of 29 tender and
20 swollen joints). ACR 20, 50, and 70 responses occurred
in 48%, 26%, and 11% in the abatacept group and in 28%,
19%, and 0% in the placebo group, respectively. In this study
the differences between active drug and placebo were
statistically significant (P < 0.05) only for ACR 20 and ACR
70 responses. Adverse events were similar between the two
treatment groups. Again, no anti-abatacept antibodies were
detected.
Phase II trials
Following the pilot studies that demonstrated efficacy of
abatacept in treating the signs and symptoms of RA, a large,
multicenter trial was reported in 2003 that confirmed these
results [3]. In this phase II trial, 339 patients with active RA,
despite methotrexate treatment, were randomly assigned to
receive infusions of abatacept 2 mg/kg, abatacept 10 mg/kg,
or placebo monthly for 6 months. Unlike the dose ranging trial
[2], in which participants received abatacept as monotherapy,
patients included in this trial were all taking methotrexate, at a
mean dose of 15–15.8 mg weekly. Their mean age was
55.0 years, 68% were women, and 87% were Caucasian.
They had longstanding disease (means of 8.9–9.7 years in
the three treatment groups). Despite this, they had relatively
mild functional impairment, with a mean Modified Stanford
Health Assessment Questionnaire score of 1.0 in all groups.
Dosing of active drug or placebo was done in a blinded
manner at baseline, 2 weeks, 4 weeks, and then monthly
through to 6 months. There were more discontinuations in the
placebo group, primarily because of lack of efficacy (n = 29);
the difference from the number of discontinuations due to
lack of efficacy in each of the two abatacept groups (13 and
12) was statistically significant (P < 0.05).
The primary end-point for the study was ACR 20 response at
6 months. Patients who discontinued therapy before 6 months
had their last efficacy observation carried forward. The
percentage of patients achieving this level of response was
60.0% in the abatacept 10 mg/kg group versus 35.3% in the
placebo group (P < 0.001). Higher levels of response (ACR
50 and ACR 70) were also achieved more frequently in the
10 mg/kg group (Fig. 2). The response in the abatacept
2 mg/kg treatment group was only statistically better than
placebo at the ACR 50 and 70 response levels (Fig. 2). A
secondary analysis, in which patients who discontinued were
considered nonresponders, yielded similar results, with
57.4% of the abatacept 10 mg/kg group responding at an
ACR 20 level versus 31.1% in the placebo group
(P < 0.001). Again, ACR 20 responses in the abatacept
2 mg/kg and placebo groups were not statistically different.
Improvement in the individual components of the ACR
response criteria was also generally greater in the 10 mg/kg
treatment group than in the 2 mg/kg group. Mean changes in
tender joint count, swollen joint count, pain, physical function,
patient and physician’s global assessment, and C-reactive
protein were all significantly greater with abatacept 10 mg/kg
than in the placebo group. Finally, improvement in all 36-item
Short Form subscales and summary scores in the abatacept
Figure 2
Percentage of patients meeting American College of Rheumatology
(ACR) 20, ACR 50, and ACR 70 response criteria after 6 months of
therapy with abatacept or placebo. From data presented by Kremer
and coworkers [3]. *P ≤ 0.05 versus placebo; †P ≤ 0.001 versus
placebo.
Figure 1
Percentage of patients meeting American College of Rheumatology
(ACR) 20, ACR 50, and ACR 70 response criteria after 85 days of
therapy with abatacept, LEA29Y, or placebo. Adapted with permission
from Moreland and coworkers [2].S24
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10 mg/kg group were clinically and statistically significant
when compared with baseline scores.
In the safety analysis for this trial, no deaths, malignancies, or
opportunistic infections were reported for any of the abatacept
treated patients during the 6 months of therapy. There were
three serious adverse events in the 10 mg/kg abatacept
group, 12 in the 2 mg/kg group, and 12 in the placebo group.
None of the serious adverse events in the high dose group
was judged to be related to the study drug. The only reported
serious infection occurred in a patient in the abatacept
2 mg/kg group, who was hospitalized because of cellulitis.
Most patients included in the study had pre-existing
antibodies to abatacept, which, although not stated in the
article, might have been due to rheumatoid factor reacting
with the Fc portion of abatacept. No patients developed
abatacept specific antibodies during the trial. One patient in
each of the two active treatment groups developed CTLA4
specific antibodies.
Patients in the phase II trial continued on blinded therapy for
an additional 6 months and were then permitted to continue
on open label therapy with abatacept. Data presented in
abstract form only [21,22] demonstrate that response to
therapy was maintained during the second 6 months of
blinded therapy, as measured by both ACR response and
improvement in 36-item Short Form parameters. Seventy-five
of the patients originally treated with methotrexate and
abatacept 10 mg/kg continued on therapy for 2 years.
Response to therapy was sustained with continued treatment.
ACR 50 response was achieved by 56% of those patients
who remained on therapy at 1 year and by 54.7% of those
who remained on therapy at 2 years [23]; 48% of patients
who remained on therapy achieved remission by Disease
Activity Score criteria at 1 year that was sustained through
2 years [24]. There were no significant differences in serious
adverse events or serious infections between active drug and
placebo during the second year of blinded therapy [25].
Phase III trials
Preliminary data from two large phase III studies of abatacept
in RA have recently been reported, at least in abstract form. In
the first, 652 patients with inadequate response to
methotrexate were randomly assigned to receive either
placebo or a fixed dose of abatacept approximating 10 mg/kg
while remaining on background methotrexate therapy [26].
The patients had a mean disease duration of approximately
8.6 years. At 1 year the percentages achieving ACR 20, ACR
50, and ACR 70 responses with active drug were 73.1%,
48.3%, and 28.8%, respectively; the corresponding
percentages for the placebo group were 39.7%, 18.2%, and
6.1%. Radiographic evaluation in this trial showed significant
reductions in progression of erosions, joint space narrowing,
and total Sharp score. Serious infections were similar
between the two treatment groups.
In the second phase III study [27], abatacept therapy was
evaluated in RA patients with an inadequate response to TNF
antagonist therapy. In this 24 week study, 391 patients who
had failed to respond adequately to at least 3 months of TNF
antagonist therapy were randomly assigned to receive either
placebo or the same fixed dose of abatacept, approximating
10 mg/kg [27]. TNF antagonist therapy was discontinued at
the time of enrollment, if this had not been done previously.
The patients in this trial had longstanding (mean disease
duration 11.4–12.2 years) and very active (Disease Activity
Score 6.9) disease, with significant functional limitations
(Health Assessment Questionairre score 1.8). ACR 20, 50,
and 70 responses in this trial were 50.4%, 20.3%, and 3.8%,
respectively; the corresponding placebo responses were
19.5%, 3.8%, and 1.5%. The incidence of adverse events,
including serious infections, was similar between the two
treatment groups.
Conclusion
Abatacept, the fusion protein combining the extracellular
portion of human CTLA4 and IgG1 Fc, has clearly been
shown to be effective at controlling the signs and symptoms
of RA, particularly at a dose of 10 mg/kg given monthly. The
2 mg/kg dose has not been shown to be as consistently
effective, even when given in combination with methotrexate
or etanercept. Trials to date have not demonstrated an
increase in adverse events, including infections, compared
with placebo. Further data will be required to confirm the
long-term safety of this therapy as a component of
combination regimens for the treatment of RA. The data
discussed in this review provide the first evidence of the
effectiveness of a co-stimulatory modulator – abatacept – in
RA, and as such this agent represents a potentially effective
new approach to the management of this disease.
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